Skip to content

Gestational Diabetes Diagnostic Methods

GD2M Study:Gestational Diabetes Diagnostic Methods

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01540396
Acronym
GD2M
Enrollment
47
Registered
2012-02-28
Start date
2012-02-29
Completion date
2014-12-31
Last updated
2016-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

Gestational Diabetes

Brief summary

This is a pilot feasibility study of 40 pregnant women to test the investigators' recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes. The two methods that are being compared are the 2 hour 75 gram OGGT (2011 ADA guidelines) versus a 1 hour 50 gram GCT + 3 hour 100 gram OGTT if the 1 hour result is abnormal (Carpenter and Coustan criteria).

Detailed description

This is a pilot feasibility study of 40 pregnant women between 24-28 weeks gestation to test the investigators recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes. Forty women 18 years of age or older will be recruited at 20-24 weeks pregnancy from the ob/gyn outpatient practices at Magee-Women's hospital (MWH). Eligible women will return to MWH main lab between 24-28 weeks gestation for the routine 1 hour 50gm glucose challenge test. Women with blood glucose values less than 200 will be randomized to receive either the fasting 2 hour 75 gm oral glucose tolerance test (OGTT)or the 3 hour 100 gm OGGT within two weeks. Gestational diabetes will be determined for the 2 hour 75 gm OGGT arm based on the 2011 ADA guidelines and the 3 hour 100 gm OGGT arm based on the Carpenter and Coustan criteria. Patients and their providers will be informed of the diagnosis of gestational diabetes, but they will be blinded to the criteria used to make the diagnosis as well as the specific results of glucose tolerance testing. Chart reviews will be conducted to assess for perinatal maternal and infant health factors (e.g.pregnancy weight, gestational weight gain, co morbidities) as well as for data on perinatal outcomes related to GDM such as macrosomia, c-sections, and birth trauma. Two brief self-administered questionnaire will assess participants' views on screening for gestational diabetes and assess participants experience with and solicit feedback on the study procedures. At the end of this pilot study, the investigators will have experience with recruitment, retention, and randomization procedures and have made the necessary protocol revisions. If successful, this feasibility study will provide the preliminary data and feasibility justification needed to conduct a larger randomized control trial to compare the effectiveness of two diagnostic methods for gestational diabetes.

Interventions

BEHAVIORALDietary modification and medications

Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Singleton pregnancy * Plan to undergo gestational diabetes screening at 24-28 weeks' gestation.

Exclusion criteria

* Existing Type 1 or Type 2 diabetes * Diabetes diagnosed early in pregnancy (less than 24 weeks gestation) * Multiple gestation (e.g. twins, triplets) * Chronic hypertension (requiring medications) * Oral, IM or IV corticosteroid use within the previous 30 days * Major congenital anomaly or anticipated preterm delivery before 28 weeks * Inability to complete 50 gram GCT before 28 completed weeks' gestation * Patients with known HIV, Hepatitis B or C virus.

Design outcomes

Primary

MeasureTime frameDescription
MacrosomiaWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)Defined as birthweight \>90th percentile for gestational age or birthweight \>4000 grams
Cesarean deliveryWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)Primary or repeat cesarean delivery
Diagnosis of gestational diabetesWill be followed from study enrollment until delivery (approximately 40 weeks' gestation)Assess how frequently a diagnosis of gestational diabetes is made

Secondary

MeasureTime frameDescription
Infant birth traumaWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)Defined as shoulder dystocia/brachial plexus injuries
Pre-eclampsia or gestational hypertensionWill be assessed from study enrollment until 30 days after deliveryNew onset hypertension +/- proteinuria
Maternal birth traumaWill be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)3rd or 4th degree perineal laceration or postpartum hemorrhage
Neonatal hypoglycemiaFirst 24 hours of lifeDefined as blood glucose less than 80 mg/dL from heel stick within 1 hour after delivery
Neonatal hyperbilirubinemiaFirst 7 days of lifeDefined as bilirubin greater than 5 mg/dL over 24 hours from heel stick

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026